Ignite Creation Date:
2024-05-06 @ 8:17 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06328049
Status:
RECRUITING
Last Update Posted:
2024-03-25
First Post:
2024-03-13
Brief Title:
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC
Sponsor:
Taixing Peoples Hospital
Organization:
Taixing Peoples Hospital
Study Overview
Official Title:
A Prospective Single-arm Exploratory Clinical Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to investigate the safety and efficacy of the prophylactic use of Trilaciclib in patients with non-small cell lung cancer NSCLC receiving platinum-based chemotherapy so as to provide more evidence-based medical evidence for the optimal diagnosis and treatment strategy in this population
Detailed Description:
This is a single-arm exploratory clinical study Eligible patients were treated with Trilaciclib before the first cycle of chemotherapy and their peripheral blood samples were tested on days 3714211 after chemotherapy At the same time the incidence of FN the use of antibiotics the safety the number of patients who delayed the second cycle of treatment the number of patients who reduced the dose of chemotherapy the number of patients who reduced the dose of chemotherapy due to neutropenia and the number of patients who discontinued chemotherapy were observed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None